Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Molecular Partners Ag (MOLN) EBT: 2020-2025

Historic EBT for Molecular Partners Ag (MOLN) over the last 5 years, with Sep 2025 value amounting to -$14,796.

  • Molecular Partners Ag's EBT rose 21.85% to -$14,796 in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.3 million, marking a year-over-year increase of 0.26%. This contributed to the annual value of -$61.4 million for FY2024, which is 10.99% up from last year.
  • As of Q3 2025, Molecular Partners Ag's EBT stood at -$14,796, which was up 99.94% from -$24.6 million recorded in Q2 2025.
  • In the past 5 years, Molecular Partners Ag's EBT registered a high of $122.2 million during Q4 2022, and its lowest value of -$69.8 million during Q4 2023.
  • For the 3-year period, Molecular Partners Ag's EBT averaged around -$17.3 million, with its median value being -$18,934 (2024).
  • Its EBT has fluctuated over the past 5 years, first surged by 1,005.57% in 2022, then tumbled by 378,595.28% in 2023.
  • Molecular Partners Ag's EBT (Quarterly) stood at -$13,406 in 2021, then decreased by 2.90% to $122.2 million in 2022, then crashed by 157.15% to -$69.8 million in 2023, then rose by 11.73% to -$61.6 million in 2024, then climbed by 21.85% to -$14,796 in 2025.
  • Its last three reported values are -$14,796 in Q3 2025, -$24.6 million for Q2 2025, and -$18,655 during Q1 2025.